#Israel #Parkinson's Disease #biotechnology #NESS ZIONA #Matricelf Ltd.

Matricelf Ltd. Expands into Parkinson's Disease Therapy Development

Matricelf Ltd. (TASE: MTLF), a prominent biotechnology firm specializing in autologous engineered tissue therapies, recently announced a critical step in their journey towards innovative Parkinson's disease treatments. On March 3, 2026, the company revealed it had signed a Memorandum of Understanding (MOU) to establish a subsidiary focused on the research, development, and commercialization of its advanced therapies targeting Parkinson's disease and related conditions.

The Strategic Importance of the New Subsidiary

This new initiative is part of Matricelf's broader strategy to concentrate resources and expertise dedicated to neurological disorders. By forming this subsidiary, Matricelf aims to enable specialized managerial focus and allocate capital efficiently. This structure ensures that the parent company can retain significant participation in the initiative while securing a pathway for targeted fundraising efforts that won't dilute equity at the parent level. As Matricelf expects to maintain a meaningful stake in the new entity, this development is seen as a way to generate long-term value for its shareholders.

Parkinson's Disease: A Growing Market

Parkinson's disease represents a significant challenge, characterized by progressive neurodegeneration that mainly affects motor functions, leading to symptoms such as tremors and rigidity. Compounding the issue, estimates from the World Health Organization indicate that the prevalence of Parkinson's disease has doubled over the past 25 years, with over 8.5 million people currently living with the condition globally. The market for Parkinson's treatment is projected to reach approximately $5.65 billion by 2024 and grow to about $7.58 billion by 2030, highlighting a substantial opportunity within this medical sector.

Transaction Structure and Future Directions

The proposed subsidiary will be established as a private Israeli company, with plans to raise $3.5 million shortly after signing the definitive agreement, which is expected within three months. Matricelf will grant the new entity an exclusive worldwide sublicense for its Parkinson's disease technology. Notably, in return, Matricelf will receive a 25% stake in the subsidiary and will participate in any future commercialization deals, earning either 12% of any income made or 2.5% of net sales, depending on which is greater.

In the event of any significant corporate changes, such as a sale of over 51% of the subsidiary or an IPO, Matricelf stands to receive a 10% success fee, signaling an arrangement designed to incentivize both parties effectively.

Furthermore, a minimum annual research and development budget of $1 million for two years will support the subsidiary's operations, ensuring a robust investment in potentially groundbreaking therapies.

Leadership and Governance Structure

Leadership roles within the subsidiary have been designated, focusing on leveraging the expertise of Matricelf's current management. Dr. Alon Sinai, currently Director and Deputy CEO, will offer guidance as an advisor, while Professor Tal Dvir will take on the role of Chief Scientist. Ron Miron, serving as the Active Chairman of Matricelf, will assume an active role in the subsidiary's governance as well.

In a public statement, Ron Miron emphasized the importance of this new initiative, indicating it signifies a vital step in Matricelf's strategic expansion into neurological indications, laying the groundwork for additional subsidiaries that can utilize their unique technological capabilities.

Next Steps and Regulatory Outlook

The completion of this transformative transaction will require the execution of the definitive agreement by April 23, 2026, the successful funding of the subsidiary, approval from related corporate bodies, and consent from relevant partners, including Ramot at Tel Aviv University, among other customary requirements. However, it is essential to note that there are inherent risks and uncertainties surrounding the closure of this agreement and the successful transition into the operational phase.

Conclusion

The establishment of a new subsidiary by Matricelf Ltd. reflects a strategic realignment to address the pressing challenges presented by Parkinson's disease. As the bioscience sector continues to evolve, Matricelf's focused approach could pave the way for innovative solutions that significantly impact the lives of millions suffering from this debilitating condition.